Publications by authors named "Elliot Barnathan"

Claim this Profile
O
Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS).
C Michael Gibson, M Cecilia Bahit, Roxana Mehran, Shamir R Mehta, Rasha Al Lamee, Elliot S Barnathan

Am Heart J· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preserving Trial Endpoint Specificity and Cause of Death Attribution in Cardiovascular Trials: Insights From MARINER.
Shea E Hogan, Mario Enrico Canonico, Robert W King, Cecilia C Low Wang, Mark R Nehler, Elliot S Barnathan

JACC Adv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary thromboprophylaxis in ambulatory symptomatic patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.
Davide Di Vece, Marco Valgimigli, Elliot Barnathan, Jean M Connors, Frank Cools

Res Pract Thromb Haemost· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials.
Judith Hsia, Alex C Spyropoulos, Gregory Piazza, Stephen Weng, Michael W Dunne, Elliot S Barnathan

Thromb Haemost· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial.
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Elliot S Barnathan

J Am Heart Assoc· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with early, late, and very late stent thrombosis among patients with acute coronary syndrome undergoing coronary stent placement: analysis from the ATLAS ACS 2-TIMI 51 trial.
Gerald Chi, Fahad AlKhalfan, Jane J Lee, Sahar Memar Montazerin, Clara Fitzgerald, Elliot Barnathan

Front Cardiovasc Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial.
Gregory Piazza, Alex C Spyropoulos, Judith Hsia, Mark Goldin, William J Towner, Elliot S Barnathan

Circulation· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease.
Albert A Volkl, Kenneth Todd Moore, Lloyd Haskell, Elliot S Barnathan

Am J Cardiovasc Drugs· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness.
Gary E Raskob, Walter Ageno, Gregory Albers, C Gregory Elliott, Jonathan Halperin, Elliot S Barnathan

J Am Heart Assoc· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study.
Alex C Spyropoulos, Gary E Raskob, Theodore E Spiro, Wentao Lu, Yoriko De Sanctis, Elliot S Barnathan

TH Open· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying a core outcome set for pulmonary sarcoidosis research - the Foundation for Sarcoidosis Research - Sarcoidosis Clinical OUtcomes Taskforce (SCOUT).
Nicola L Harman, Sarah L Gorst, Paula R Williamson, Elliot S Barnathan, Robert P Baughman

Sarcoidosis Vasc Diffuse Lung Dis· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial.
Alex C Spyropoulos, Mark Goldin, Walter Ageno, Gregory W Albers, C Gregory Elliott, Elliot S Barnathan

TH Open· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
Alex C Spyropoulos, Gary E Raskob, Alexander T Cohen, Walter Ageno, Jeffrey I Weitz, Elliot S Barnathan

Circulation· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis.
Concetta Lipardi, C Gregory Elliott, Chiara L Sugarmann, Lloyd Haskell, Alex C Spyropoulos, Elliot S Barnathan

Clin Appl Thromb Hemost· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older.
Walter Ageno, Renato D Lopes, Mark Goldin, Roger D Yusen, Gregory W Albers, Elliot S Barnathan

J Thromb Haemost· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
Gary E Raskob, Alex C Spyropoulos, Theodore E Spiro, Wentao Lu, Zhong Yuan, Elliot S Barnathan

J Am Heart Assoc· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scout - sarcoidosis outcomes taskforce. A systematic review of outcomes to inform the development of a core outcome set for pulmonary sarcoidosis.
Nicola L Harman, Sarah L Gorst, Paula R Williamson, Elliot S Barnathan, Robert P Baughman

Sarcoidosis Vasc Diffuse Lung Dis· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study.
Warren H Capell, Elliot S Barnathan, Gregory Piazza, Alex C Spyropoulos, Judith Hsia

Am Heart J· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Risk Assessment of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants: A Network Study Across Four Observational Databases in the USA.
James Weaver, Azza Shoaibi, Huy Q Truong, Leila Larbi, Shujian Wu, Elliot Barnathan

Drug Saf· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients.
Gary E Raskob, Alex C Spyropoulos, Alexander T Cohen, Jeffrey I Weitz, Walter Ageno, Elliot S Barnathan

J Am Heart Assoc· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inference from longitudinal laboratory tests characterizes temporal evolution of COVID-19-associated coagulopathy (CAC).
Colin Pawlowski, Tyler Wagner, Arjun Puranik, Karthik Murugadoss, Liam Loscalzo, Elliot S Barnathan

Elife· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients.
Alex C Spyropoulos, Walter Ageno, Gregory W Albers, C Gregory Elliott, Jonathan L Halperin, Elliot S Barnathan

J Am Coll Cardiol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hospital-based use of thromboprophylaxis in patients with COVID-19.
Alex C Spyropoulos, Walter Ageno, Elliot S Barnathan

Lancet· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
Jeffrey I Weitz, Gary E Raskob, Alex C Spyropoulos, Theodore E Spiro, Yoriko De Sanctis, Elliot S Barnathan

Thromb Haemost· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis.
Alex C Spyropoulos, Concetta Lipardi, Jianfeng Xu, Colleen Peluso, Theodore E Spiro, Elliot S Barnathan

TH Open· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis